Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Neil Horowitz MD
Closed to Accrual
Closure to Accrual: 2/20/2020
To determine the efficacy of cisplatin, gemcitabine, and Intensity-Modulated Radiation Therapy (IMRT) in achieving a complete pathologic response when used for the primary treatment of locally-advanced squamous cell carcinoma of the vulva.
Patients with locally-advanced, previously untreated squamous cell T2 or T3 primary vulvar tumors (N0-3,M0) not amenable to surgical resection by standard radical vulvectomy
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.